Humanity and Health Research Centre
14
3
3
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.1%
1 terminated/withdrawn out of 14 trials
90.9%
+4.4% vs industry average
29%
4 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
Role: lead
Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF
Role: lead
Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid
Role: lead
Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
Role: lead
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
Role: lead
Longitudinal Observational Study Of Chinese With NAFLD/NASH
Role: lead
Nonalcoholic Steatohepatitis in Chinese Children
Role: lead
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
Role: lead
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients
Role: lead
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
Role: lead
SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients
Role: lead
Triple Combination DAAs for Treating HCV GT1b Subjects
Role: lead
Neutrino Regimen for Treatment-experienced HCV GT1 Patients
Role: lead
Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects
Role: lead
All 14 trials loaded